38216-93-2

Upstream product

• 776-88-5 5,5-dimethyl-2-phenyl-[1,3]dioxane 
• 66582-32-9 3-(benzyloxy)-2,2-dimethylpropan-1-ol 
• 100-39-0 benzyl bromide 
• 100-52-7 benzaldehyde 
• 774-48-1 (diethoxymethyl)benzene 
• 14002-80-3 Methyl 2,2-dimethyl-3-hydroxypropionate 
• 96556-40-0 methyl-3-(benzyloxy)-2.2-dimethylpropionate 
• 100-44-7 benzyl chloride 
• 126-30-7 2,2-Dimethyl-1,3-propanediol 
• 1125-88-8 benzaldehyde dimethyl acetal 
• 75-24-1 trimethylaluminum 

Downstream Products

• 464186-78-5 1-benzyloxy-6-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-5-trimethylsilanylmethyl-hex-5-en-3-ol 
• 957791-54-7 (E)-N-(3-(benzyloxy)-2,2-dimethylpropylidene)-4-methoxybenzenamine 
• 957791-46-7 (3R,4S)-3-acetoxy-4-(2-benzyloxy-1,1-dimethylethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 865154-57-0 (3S,4R)-4-(2-benzyloxy-1,1-dimethylethyl)-3-hydroxy-1-(4-methoxyphenyl)azetidin-2-one 
• 865154-54-7 (3R,4S)-3-hydroxy-4-(2-benzyloxy-1,1-dimethylethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 957791-44-5 (3R,4S)-3-hydroxy-4-(1,1-dimethyl-2-hydroxyethyl)-1-(4-methoxyphenyl)azetidin-2-one 
• 957791-56-9 (4R)-4-(2-benzyloxy-1,1-dimethylethyl)-1-(4-methoxyphenyl)azetidine-2,3-dione 
• 957791-68-3 (3R,4S)-4-(2-benzyloxy-1,1-dimethylethyl)-3-(tert-butyldimethylsilanyloxy)-1-(4-methoxyphenyl)azetidin-2-one 

Relevant academic research and scientific papers

IMPROVED PROCESS FOR THE PREPARATION OF TEZACAFTOR INTERMEDIATE

The present invention relates to an improved process for the preparation of tezacaftor intermediate compound of formula II. More particularly, the present invention relates to an improved, commercially viable process for the preparation of tezacaftor inte

Evaluation of the Pharmacophoric Role of the O-O Bond in Synthetic Antileishmanial Compounds: Comparison between 1,2-Dioxanes and Tetrahydropyrans

Leishmaniases are neglected diseases that can be treated with a limited drug arsenal; the development of new molecules is therefore a priority. Recent evidence indicates that endoperoxides, including artemisinin and its derivatives, possess antileishmanial activity. Here, 1,2-dioxanes were synthesized with their corresponding tetrahydropyrans lacking the peroxide bridge, to ascertain if this group is a key pharmacophoric requirement for the antileishmanial bioactivity. Newly synthesized compounds were examined in vitro, and their mechanism of action was preliminarily investigated. Three endoperoxides and their corresponding tetrahydropyrans effectively inhibited the growth of Leishmania donovani promastigotes and amastigotes, and iron did not play a significant role in their activation. Further, reactive oxygen species were produced in both endoperoxide-and tetrahydropyran-Treated promastigotes. In conclusion, the peroxide group proved not to be crucial for the antileishmanial bioactivity of endoperoxides, under the tested conditions. Our findings reveal the potential of both 1,2-dioxanes and tetrahydropyrans as lead compounds for novel therapies against Leishmania.

Stereoselective Synthesis of γ-Butyrolactones Subunit of Polycavernoside A

An efficient and versatile linear synthesis of γ-butyrolactone subunit of polycavernolide A has been reported in 14.2% overall yield with 10 linear steps by employing Sharpless asymmetric epoxidation, ring-closing metathesis, and diastereoface selective h

SUBSTITUTED TRICYCLICS AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

PYRAZOLYL SUBSTITUTED TETRAHYDROPYRANYLSULFONES

The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Regioselective dihydropyran formation from 4-iodo-2,6-disubstituted tetrahydropyran derivatives using In(OAc)3/LiI system as the promoter

The rapid and regioselective synthesis of a series of 2,6-disubstituted dihydropyranic building-blocks bearing an oxygenated side chain is described. The corresponding 4-iodo tetrahydropyran precursors, easily prepared by Prins cyclization, underwent regi

Fragment-based drug design of novel pyranopyridones as cell active and orally bioavailable tankyrase inhibitors

Tankyrase activity has been linked to the regulation of intracellular axin levels, which have been shown to be crucial for the Wnt pathway. Deregulated Wnt signaling is important for the genesis of many diseases including cancer. We describe herein the discovery and development of a new series of tankyrase inhibitors. These pyranopyridones are highly active in various cell-based assays. A fragment/structure based optimization strategy led to a compound with good pharmacokinetic properties that is suitable for in vivo studies and further development.

Total synthesis and complete structural assignment of Yaku'amide A

Here we report the first total synthesis and the complete stereochemical assignment of yaku'amide A. Yaku'amide A (1) was isolated from a sponge Ceratopsion sp. as an extremely potent cytotoxin. Its structure was determined except for the C4-stereochemist

PYRANOPYRIDONE INHIBITORS OF TANKYRASE

There are provided compounds of the formula or a pharmaceutically acceptable salt thereof wherein X, M, Y, R1 and R2 are as defined herein. The compounds have activity as anticancer agents.

Ruthenium-catalyzed reductive coupling of 1,3-enynes and aldehydes by transfer hydrogenation: Anti-diastereoselective carbonyl propargylation

Under the conditions of ruthenium-catalyzed transfer hydrogenation employing isopropanol as a source of hydrogen, isopropoxy-substituted enyne 1 b and aldehydes 3 a-3 l engage in reductive coupling to provide products of propargylation 4 a-4 l with good to complete levels of anti- diastereoselectivity. The unprotected tertiary hydroxy moiety of isopropoxy enyne 1 b is required to enforce diastereoselectivity. Deuterium-labeling studies corroborate reversible enyne hydrometalation in advance of carbonyl addition. As demonstrated in the conversion of 4 f-h and 4 k to 5 f-h and 5 k, the isopropoxy group of the product is readily cleaved upon exposure to aqueous sodium hydroxide to reveal the terminal alkyne. Unprotected coupling is better! Ruthenium-catalyzed transfer hydrogenation of enynes in the presence of aldehydes promotes reductive C-C coupling to provide products of propargylation with good to complete levels of anti-diastereoselectivity (see scheme). The unprotected hydroxy group of the isopropoxy-substituted enyne is required to enforce high levels of anti-diastereoselectivity. Copyright